ArticleESMO open2024

Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021.

V Grumberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.